Pembrolizumab is an immune checkpoint inhibitor approved for the treatment of patients with unresectable or metastatic melanoma. Appearance of bone metastases, either osteolytic or osteoblastic, during treatment qualifies as disease progression. We report the case of a 64-year-old White woman with a metastatic melanoma undergoing second-line treatment with pembrolizumab. At first evaluation, after 3 months of therapy, computed tomography scans showed the onset of osteosclerotic lesions and a significant reduction in all the previously identified metastases; on the contrary, a fluorine-18-fluorodeoxyglucose PET showed the normalization of fluorine-18-fluorodeoxyglucose uptake in all the baseline lesions, including bone metastases. Osteoblastic response, consisting of occurrence of new osteoblastic lesions on computed tomography imaging, as a consequence of an osteoblastic reaction of previously undetectable bone metastases, has been reported in some cancers that receive treatments such as chemotherapy, hormonal or targeted therapy. However, it had never been reported in patients with melanoma treated with immunotherapy. An apparent worsening of bone imaging on standard computed tomography scan in patients under checkpoint inhibitor should not lead to modification of treatment strategy, because misinterpretation as disease progression may lead to the premature cessation of a beneficial treatment and finally have a negative effect on patients' clinical outcome.
Pembrolizumab is an immune checkpoint inhibitor approved for the treatment of patients with unresectable or metastatic melanoma. Appearance of bone metastases, either osteolytic or osteoblastic, during treatment qualifies as disease progression. We report the case of a 64-year-old White woman with a metastatic melanoma undergoing second-line treatment with pembrolizumab. At first evaluation, after 3 months of therapy, computed tomography scans showed the onset of osteosclerotic lesions and a significant reduction in all the previously identified metastases; on the contrary, a fluorine-18-fluorodeoxyglucose PET showed the normalization of fluorine-18-fluorodeoxyglucose uptake in all the baseline lesions, including bone metastases. 
Introduction
Incidence of bone metastases from malignant melanoma ranges from 11 to 17% in most clinical series, whereas autopsy series reveal that skeletal involvement can be more common (23-49%) [1] [2] [3] [4] .
Appearance of bone metastases, either osteolytic or osteoblastic, during treatment qualifies as disease progression. However, osteoblastic response, consisting of occurrence of new osteoblastic lesions on computed tomography (CT) imaging during treatment, as a consequence of an osteoblastic reaction of previously undetectable bone metastases, has been reported in some cancers [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Two therapeutic strategies have improved survival for patients with advanced melanoma in recent years: immunotherapy with checkpoint inhibitors and targeted therapies blocking BRAF and MEK. BRAF and MEK inhibitors are indicated for the ∼ 40-50% of patients with BRAF V600 mutations, whereas immunotherapies are effective independent of BRAF mutational status.
Pembrolizumab is an immune checkpoint inhibitor, registered for the treatment of patients with unresectable or metastatic melanoma.
Here, we present a case of osteoblastic response following the administration of immunotherapy for advanced melanoma.
Case description
In 1985, a 32-year-old White woman underwent resection of cutaneous melanoma in the right popliteal fossa ( Fig. 1) . In April 2012, she developed homolateral inguinal lymph node recurrence, and after pathologic confirmation, she was subjected to iliac and inguino-femoral lymph node dissection in June 2012. The histologic examination showed presence of melanoma metastases in 16 of the 21 removed lymph nodes. In November 2012, she experienced a second groin and abdominal lymph node recurrence. As gene mutational analysis showed the presence of BRAF V600E activating mutation, she received first-line treatment with BRAF kinase inhibitor vemurafenib from December 2012 to January 2017. In January 2016, cobimetinib 60 mg/day was added, but it was discontinued after 2 months because of gastrointestinal toxicity.
A fluorine-18-fluorodeoxyglucose ( 18 F-FDG)-PET/CT performed in January 2017 showed pulmonary, bone and lymph nodal progression of disease. Notably, bone metastases were evident only on the PET images (Figs 2a, b, 3a and b) but were not detectable on a contrast-enhanced CT scan performed a few days later.
Therefore, since February 2017, a second-line treatment with immune checkpoint inhibitor pembrolizumab has been administered. The first CT evaluation, performed after four administrations, documented disappearance of some lympho-nodal and pulmonary metastases and reduction in all of the previously identified metastatic sites. CT also showed the appearance of osteoblastic lesions at the fifth lumbar vertebra and at the anterior superior iliac spine (Figs 2c and 3c) where the baseline PET 18 F-FDG-uptake was positive (Figs 2b and 3b) . On the contrary, 18 F-FDG-PET showed the normalization of 18 F-FDG uptake in all the baseline lesions, including bone metastases (Figs 2d and 3d) . Furthermore, these lesions were totally asymptomatic, and the patient did not receive concurrent medications known to interfere with bone metabolism. Although no pathologic confirmation was obtained, the osteoblastic lesions that developed during therapy were considered likely to be an osteoblastic response to immunotherapy and the treatment was continued. A following tumor assessment performed in September 2017 documented a further response in the remaining metastases and a dimensional reduction of the bone lesions (Fig. 4) .
Conclusion
Generally, in the assessment of objective response to anticancer agents, bone metastases are classified as nontarget lesions and therefore 'not evaluable' for response. However, according to immune Response Evaluation Criteria in Solid Tumors guideline, the appearance of Diagram summarizing disease history. new nontarget lesions, including lytic or osteoblastic bone metastases, is a criterion for defining immune unconfirmed progressive disease or immune confirmed progressive disease, if a further increase in size (or in the number of new lesions) is observed in the following imaging assessment [22] . 18 F-FDG-PET is not qualified, at the moment, as a standard diagnostic tool to assess response to immunotherapy treatment.
Osteoblastic reaction/response consists in the appearance of new osteoblastic lesions not visible at baseline and detected radiographically only after sclerotic healing reaction has occurred, in the presence of stable or responding disease in other tumor sites. This phenomenon is well documented in patients with prostate and breast cancer receiving hormonal or chemotherapy treatment [5] [6] [7] [8] [9] . A few cases have also been reported in patients with small cell lung and gastric cancer responding to chemotherapy [10] [11] [12] [13] [14] . In epidermal growth factor receptor gene-addicted and anaplastic lymphoma kinase gene rearranged non-small-cell lung cancer population treated with targeted therapy, osteoblastic reaction has also been described, reaching prevalence higher than 20% in epidermal growth factor receptor geneaddicted patients [15] [16] [17] [18] [19] [20] . More recently, Bottlaender et al. [21] have documented osteosclerotic changes occurred in three patients with metastatic melanoma under BRAF inhibitor treatment. Pembrolizumab, a highly selective, humanized monoclonal IgG4κ isotype antibody against PD-1, can disrupt the engagement of PD-1 with its ligands and impede relative inhibitory signals in T cells. To date, it is indicated for the treatment of patients with melanoma, nonsmall-cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma and microsatellite instability-high solid cancer.
To our knowledge, this is the first case reporting osteoblastic bone response during immunotherapy treatment. The findings of the first CT assessment were classified as an unconfirmed bone progression according to immune Response Evaluation Criteria in Solid Tumors guideline. However, considering the objective radiological response at extra-skeletal sites and the negative 18 F-FDG-PET/ CT result, the bone changes were interpreted as an 'osteoblastic response' of previously CT-undetectable bone metastases. Pembrolizumab was therefore continued with further benefit to the patient.
With the increasing use of immunotherapy, it is likely to see more cases of osteoblastic response, similar to the one described in this case report. Therefore, it is important that physicians and radiologists involved in the care of patients with advanced melanoma are aware of this phenomenon. In the presence of a clinical benefit and tumor response in extra-skeletal sites, an apparent worsening of bone imaging at standard CT scan should not lead to modify treatment strategy, because misinterpretation as disease progression may lead to the premature cessation of a beneficial treatment and finally have a negative effect on patients' clinical outcome. Furthermore, 18 F-FDG-PET/CT may be a more useful diagnostic tool, as compared with CT scan, in assessing bone metastases response to immunotherapy and other biological anticancer agents.
